- ￥2020
- Solarbio
- 北京
- IP15601
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Stroe at -20℃，6 months.
- 保质期：
Stroe at -20℃，6 months.
- 英文名：
PHA-793887(10mM in DMSO,Sterile）
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
718630-59-2
- 规格：
1ml
| 基本信息 | |
| CAS | No.718630-59-2 |
| 英文名称 | PHA-793887(10mM in DMSO,Sterile） |
| 分子式 | C19H31N5O2 |
| 分子量 | 361.48 |
| 溶解性 | 请根据自己的实验要求使用。 |
| 外观(性状) | 无菌溶液 |
| 储存条件 | Stroe at -20℃，6 months. |
| 靶点 | CDK |
| 通路 | Cell Cycle |
| 背景说明 | PHA-793887 是一种有效的，ATP 竞争性的 CDK 抑制剂。 |
| 生物活性 | PHA-793887 is a potent， ATP-competitive CDK inhibitor， can inhibit Cdk2， Cdk1， Cdk4， and Cdk9 with IC50s of 8 nM， 60 nM， 62 nM and 138 nM， respectively， and also inhibits glycogen synthase kinase 3β with an IC50 of 79 nM.[1-4] |
| In Vitro | PHA-793887 partially inhibits Rb phosphorylation at 1 μM and almost completely at 3 μM， in A2780 tumor cell line. PHA-793887 (1 μM) partially inhibits phosphorylation of the Cdk2 substrates Rb and NPM in A2780 tumor cell line. PHA-793887 (6 μM) significantly inhibits Rb and NPM phosphorylation in MCF7 cell line[1]. PHA-793887 shows cytotoxic activities against leukemic cell lines in vitro， with IC50 ranging from 0.3 to 7 μM. In colony assays， PHA-793887 is highly cytotoxic for leukemia cell lines， with an IC50 apoptosis at the highest dose of 5 μM. PHA-793887 is a novel inhibitor of several cdk， including cdk1， cdk2， cdk4， cdk5， cdk7， and cdk9 with IC50 in the 5 to 140 nM range[3]. |
| 细胞实验 | PHA-793887 induces tumor growth inhibition in the range of 50% at dose of 15 mg/kg to 75% at dose of 30 mg/kg in CD-1 nude mice. PHA-793887 (30 mg/kg， i.v.) also induces significant downregulation of the 58-gene panel in the skin of CD-1 mice[1]. PHA-793887 (20 mg/kg， i.v.) induces tumor regression in the HL60 model. In the K562 model， PHA-793887 significantly reduces tumor growth. Moreover， PHA-793887 (20 mg/kg， i.v.) inhibits human primary leukemia growth in engraftment setting in vivo[3]. |
| 细胞实验 | Cytotoxicity assays are performed using the Alamar blue vital dye. For each cell line， preliminary dose?response curves are performed to establish the cell-concentration range， giving a linear relationship with fluorescence. For cell lines， 5，000 to 20，000 cells are plated in 200 μL complete medium in 96-well plates， in the presence or absence of increasing doses of drugs (0.01?10 μM). For ALL-2 and AML-PS leukemias 10 × 105 cells/well are plated in StemSpanSFEM medium and treated with the same range of drug concentrations. Peripheral blood mononuclear cells and cord blood CD34+ cells are plated 1 × 105 cells/well in presence or absence of 1 μg/mL phytohemagglutin or growth factor cocktail (50 ng/mL stem cell factor， 20 ng/mL each of granulocyte-macrophage colony-stimulating factor， granulocyte colony-stimulating factor， interleukin-3， interleukin-6， and 3 U/mL erythropoietin)， respectively. In all cases， after 48 hours culture， 1/10 volume Alamar blue solution is added and incubated overnight. The plates are then read in a fluorimeter with excitation at 535 nm and emission at 590 nm. Cytotoxicity is calculated as percentage of fluorescence with respect to untreated control， after subtracting for background fluorescence in absence of cells.[1-4] |
| 动物实验 | 107 HL60 and K562 cells are inoculated subcutaneously in SCID mice. Animals are randomized in seven mice per group. PHA-793887 is administered at 20 mg/kg intravenous (IV) once a day， continuously for 10 days (from day 9 to day 18) in HL60 model and with a two 5-day cycles (from day 9 to day 13 and from day 17 to day 21) in K562-bearing mice. Glivec is orally administered for 9 consecutive days from day 9 onward in the K562 xenograft model. Tumor growth and net body weight are evaluated twice a week. The tumor weight is calculated according to the following formula: tumor weight = length (mm) × width2 (mm) /2. The effect of the anticancer treatment is determined as the delay in onset of an exponential growth of tumors. This delay (T ? C value) is defined as the difference of median time (in days) required for the tumors of treatment (T) and control groups (C) to reach a predetermined size. Toxicity is evaluated on the basis of the body weight reduction.[1-4] |
| 数据来源文献 | [1]. Locatelli G， et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer Ther. 2010 May;9(5):1265-73. [2]. Massard C， et al. A first in man， phase I dose-escalation study of PHA-793887， an inhibitor of multiple cyclin-dependent kinases (CDK2， 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15. [3]. Alzani R， et al. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol. 2010 Apr;38(4):259-269.e2. [4]. Brasca MG， et al. Optimization of 6，6-dimethyl pyrrolo[3，4-c]pyrazoles: Identification of PHA-793887， a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
要进入核糖体上进行翻译，需要一段富含嘌呤的核苷酸序列与大肠杆菌16S rRNA3，末端富含嘧啶的序列互补，是核糖体的识别位点。 46、 反义核酸技术：是通过合成一种短链且与DNA或RNA互补的，以DNA或RNA为目标抑制翻译的反义分子，干扰目的基因的转录、剪接、转运、翻译等过程的技术。 47、 核酸探针：探针是指能与某种大分子发生特异性相互作用，并在相互作用之后可以检测出来的生物大分子。核酸探针是指能识别特异碱基顺序的带有标记的一段DNA或RNA分子。 48、 周期蛋白：是一类呈细胞周期特异
技术资料暂无技术资料 索取技术资料
IP15601 PHA-793887(10mM in DMSO,Sterile） 细胞周期 索莱宝
￥2020
